Transient Diabetes Insipidus After Vasopressin Discontinuation

被引:0
作者
Chai, Audrey L. [1 ]
Rakocevic, Rastko [2 ]
El-Baba, Firas M. [2 ]
Killu, Keith [2 ]
机构
[1] Univ Southern Calif, Dept Med, Los Angeles, CA 90007 USA
[2] Univ Southern Calif, Dept Med, Div Pulm Crit Care & Sleep Med, Los Angeles, CA 90007 USA
关键词
vasopressor; hypernatremia; polyuria; vasopressin; shock; intensive care; diabetes insipidus; VASODILATORY SHOCK; MANAGEMENT;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Vasopressin infusion is commonly used in intensive care settings during states of advanced vasodilatory shock for its vasoconstrictive properties. Vasopressin also acts on renal tubular cell receptors in the collecting ducts of kidneys to allow for water reabsorption. The sudden discontinuation of vasopressin infusion can lead to the development of transient diabetes insipidus (DI) with classic findings of polyuria, dilute urine, and hypernatremia. We report the case of a 59 -year -old male who underwent an emergent bedside cricothyrotomy procedure secondary to papillary carcinoma of the thyroid and subsequently developed septic shock requiring initiation of vasopressin infusion for hemodynamic support. He remained on vasopressin for five days before the infusion was discontinued after clinical improvement. Within 12 hours of vasopressin discontinuation, the patient developed polyuria (> 3 L/day urine output) with volumes as high as 1 L per hour. His serum sodium levels increased more than 10 mmol/L from 137 to 149 mmol/L. This case is unique from prior reports, as our patient was without any neurological or neurosurgical comorbidities that would predispose him to an organic central cause of DI. Furthermore, the patient's largevolume diuresis and serum abnormalities spontaneously self -improved within 24 hours without significant medical intervention. In conclusion, this case adds to a growing number of reports of transient DI following vasopressin withdrawal, demonstrating the need to formally recognize this occurrence as a potential consequence of vasopressin use in intensive care settings.
引用
收藏
页数:4
相关论文
共 14 条
  • [1] Management of vasodilatory shock after cardiac surgery: Identification of predisposing factors and use of a novel pressor agent
    Argenziano, M
    Chen, JM
    Choudhri, AF
    Cullinane, S
    Garfein, E
    Weinberg, AD
    Smith, CR
    Rose, EA
    Landry, DW
    Oz, MC
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1998, 116 (06) : 973 - 980
  • [2] The V2 vasopressin receptor mutations and fluid homeostasis
    Birnbaumer, M
    [J]. CARDIOVASCULAR RESEARCH, 2001, 51 (03) : 409 - 415
  • [3] Transient Diabetes Insipidus After Discontinuation of Vasopressin in Neurological Intensive Care Unit Patients: Case Series and Literature Review
    Bohl, Michael A.
    Forseth, James
    Nakaji, Peter
    [J]. WORLD NEUROSURGERY, 2017, 97 : 479 - 488
  • [4] Transient Central Diabetes Insipidus Occurring After Vasopressin Infusion
    Cristiano, Elizabeth A.
    Harris, Ashley
    Grdinovac, Kristin
    [J]. AACE CLINICAL CASE REPORTS, 2022, 8 (01): : 8 - 10
  • [5] Vasopressin and its analogues in shock states: a review
    Demiselle, Julien
    Fage, Nicolas
    Radermacher, Peter
    Asfar, Pierre
    [J]. ANNALS OF INTENSIVE CARE, 2020, 10 (01)
  • [6] Arginine vasopressin in advanced vasodilatory shock -: A prospective, randomized, controlled study
    Dünser, MW
    Mayr, AJ
    Ulmer, H
    Knotzer, H
    Sumann, G
    Pajk, W
    Friesenecker, B
    Hasibeder, WR
    [J]. CIRCULATION, 2003, 107 (18) : 2313 - 2319
  • [7] Diabetes Insipidus and Syndrome of Inappropriate Antidiuretic Hormone in Critically Ill Patients
    Harrois, Anatole
    Anstey, James R.
    [J]. CRITICAL CARE CLINICS, 2019, 35 (02) : 187 - +
  • [8] Physiology of vasopressin relevant to management of septic shock
    Holmes, CL
    Patel, BM
    Russell, JA
    Walley, KR
    [J]. CHEST, 2001, 120 (03) : 989 - 1002
  • [9] Transient diabetes insipidus after discontinuation of therapeutic vasopressin
    Kristeller, JL
    Sterns, RH
    [J]. PHARMACOTHERAPY, 2004, 24 (04): : 541 - 545
  • [10] Landry DW, 1997, CIRCULATION, V95, P1122